Gene · 2175
Papers3,803
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 3,803
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? | Cancer Chemother Pharmacol | 2024 | 37934252 | PubTator, text mining | PubMed |
| Optical genome mapping reveals balanced and unbalanced genetic changes associated with tumor-forming potential in an early-stage prostate cancer epithelial subline (M2205). | Mol Genet Genomic Med | 2024 | 37902189 | PubTator, text mining | PubMed |
| Expression of "DNA damage response" pathway genes in diffuse large B-cell lymphoma: The potential for exploiting synthetic lethality. | Hematol Oncol | 2024 | 37795760 | PubTator, text mining | PubMed |
| Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer. | J Racial Ethn Health Disparities | 2024 | 36810713 | PubTator, text mining | PubMed |
| Primary lymphoma of bone in children: Three case reports and literature review. | Pediatr Discov | 2023 | 40625579 | PubTator, text mining | PubMed |
| Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma. | Biomedicines | 2023 | 38275384 | PubTator, text mining | PubMed |
| Neurological abnormalities among pediatric patients with sickle cell disease in Saudi Arabia: a single-center retrospective study. | Front Pediatr | 2023 | 38269289 | PubTator, text mining | PubMed |
| Case report: A safeguard in the sea of variants of uncertain significance: a case study on child with high risk neuroblastoma and acute myeloid leukemia. | Front Oncol | 2023 | 38260858 | PubTator, text mining | PubMed |
| Genomic profiling of relapsed small cell lung cancer reveals potential pathways of therapeutic targets. | J Thorac Dis | 2023 | 38249912 | PubTator, text mining | PubMed |
| Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer. | Curr Oncol | 2023 | 38248100 | PubTator, text mining | PubMed |
| Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility. | Int J Mol Sci | 2023 | 38203561 | PubTator, text mining | PubMed |
| Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer. | Int J Mol Sci | 2023 | 38203248 | PubTator, text mining | PubMed |
| Exploiting the DNA Damage Response for Prostate Cancer Therapy. | Cancers (Basel) | 2023 | 38201511 | PubTator, text mining | PubMed |
| Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction. | Cancers (Basel) | 2023 | 38201431 | PubTator, text mining | PubMed |
| PD-L1+ diffuse large B-cell lymphoma with extremely high mutational burden and microsatellite instability due to acquired PMS2 mutation. | Cold Spring Harb Mol Case Stud | 2023 | 38199780 | PubTator, text mining | PubMed |
| AID-induced CXCL12 upregulation enhances castration-resistant prostate cancer cell metastasis by stabilizing β-catenin expression. | iScience | 2023 | 38162032 | PubTator, text mining | PubMed |
| TICRR serves as a prognostic biomarker in lung adenocarcinoma with implications in RNA epigenetic modification, DDR pathway, and RNA metabolism. | Front Oncol | 2023 | 38152367 | PubTator, text mining | PubMed |
| The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations. | Front Oncol | 2023 | 38146508 | PubTator, text mining | PubMed |
| NMR and Docking Calculations Reveal Novel Atomistic Selectivity of a Synthetic High-Affinity Free Fatty Acid vs. Free Fatty Acids in Sudlow's Drug Binding Sites in Human Serum Albumin. | Molecules | 2023 | 38138481 | PubTator, text mining | PubMed |
| Molecular, Cellular, and Technical Aspects of Breast Cancer Cell Lines as a Foundational Tool in Cancer Research. | Life (Basel) | 2023 | 38137912 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2175/papers?page=13